Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. is a development-stage medical technology company developing blood purification and dialysis-like therapies for cardiovascular disease, cancer and severe inflammatory conditions. News about SIGY commonly covers Sigyn Therapy, Sigyn CardioDialysis, ImmunePrep, ChemoPrep and ChemoPure, including product-development presentations, annual-report references and shareholder communications.
Company updates also include capital-structure actions such as its completed reverse stock split and disclosures tied to OTCQB trading, SEC reporting and the development pathway for its therapeutic candidates.
Sigyn Therapeutics, Inc. (OTCMarkets: SIGY) announced that its Chairman and CEO, Jim Joyce, will present a live webinar on February 16, 2021, at 12:00 pm ET. The company focuses on treating life-threatening inflammatory conditions caused by Cytokine Storm Syndrome, aiming to address a significant unmet need in global health. Sigyn Therapy is designed to mitigate this syndrome, which is linked to high mortality rates, especially during COVID-19. This press release includes forward-looking statements about potential risks and uncertainties affecting the company's performance.